Table 1.
Demographic and clinical characteristic of study population (n = 55)
| Characteristics | Value |
|---|---|
| Gender (n, %) | |
| Female | 23 (42) |
| Male | 32 (58) |
| Age, year, mean (SD) | 37.3 (10.1) |
| BMI, kg/m2, mean (SD) | 24.3 (3.7) |
| NYHA class (n, %) | |
| I, I–II | 20 (36.4) |
| II, II–III | 28 (50.9) |
| III | 7 (12.7) |
| GDMT, number (%) | 55 (100) |
| GDMT at maximum recommended dose, number (%) | 10 (18.2) |
| LVEF, %, mean (SD) | 21.4 (9.4) |
| Creatinine (mg/dL), mean (SD) | 0.8 (0.2) |
| 6MWT (metre), mean (SD) | 395.9 (139.8) |
| Pro BNP (ng/dL), median (IQR) | 835 (132–1700) |
| Haemoglobin (g/L), mean (SD) | 13.9 (2) |
| Serum albumin (g/L) | 42.9 (5) |
| Serum total protein (g/L) | 69.8 (6.4) |
| Sodium (mmol/L) | 137.3 (4.2) |
| Potassium (mmol/L) | 4.2 (0.4) |
| Triglyceride (mg/dL) | 156.6 (86) |
| Cholesterol (mg/dL) | 177.9(54.7) |
| HDL (mg/dL) | 40.6 (11.2) |
| LDL (mg/dL) | 102.5 (35.4) |
6MWT, 6‐min walk test; BMI, body mass index; BNP, brain natriuretic peptide; GDMT, guideline‐directed medical therapy; HDL, high density lipoprotein; IQR, interquartile range; LDL, low density lipoprotein; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SD, standard deviation.